


**Supplemental figure 1. Treatment with 25D1.16 mAb does not cause the depletion of SIINFEKL presenting cells.** CD45.1+ splenocytes were coated with SIINFEKL peptide then adoptively transferred into CD45.2 hosts which were treated with 500  $\mu$ g of either rat IgG or 25D1.16 mAb. Three days after transfer the spleens were harvested and transferred cells detected by flow cytometry. **(A)** B220- CD11c-, CD11c+ and B220+ splenocytes all expressed surface MHC:SIINFEKL complexes as detected by Alexa 647 conjugated 25D1.16 mAb. **(B)** The percentage of transferred cells recovered from either IgG or 25D1.16 mAb treated mice is represented graphically.



**Supplemental Figure 2. Y-Ae affects the response through inhibition of proliferation.  $1 \times 10^5$  CFSE-labeled CD45.2 TEa cells were transferred and 24 hrs later the mice were injected with 100ug Y-Ae and infected with VSV-GSE. At 3 and 5 days after infection the expansion and CFSE dilution of the Tea cells was measured by flow cytometry.**

Day after infection	Control IgG	25D.1.16
4	$2.7 \pm 0.3 \times 10^4$	$3.0 \pm 0.8 \times 10^4$
8	Not detected	Not detected

**Supplemental Table 1.** Virus titers in the lung are not affected by 25D.1.16 treatment. Mice were infected with influenza virus (WSN-ova) and the next day were treated with 250ug of control IgG or 25D.1.16. Lungs were harvested 4 and 8 days after infection and virus titers were determined by plaque assay using MDCK cells. Values represent the average titers per whole lung +/- the SD of 3 mice per group. No statistically significant difference was detected between the groups.